Bank of America Securities Reaffirms Their Buy Rating on Qiagen (QGEN)

Bank of America Securities analyst Michael Ryskin maintained a Buy rating on Qiagen (QGEN – Research Report) today. The company’s shares opened today at $39.54.

According to TipRanks, Ryskin is a 3-star analyst with an average return of 3.7% and a 51.09% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as Illumina, Idexx Laboratories, and Zoetis.

In addition to Bank of America Securities, Qiagen also received a Buy from Deutsche Bank’s Falko Friedrichs in a report issued yesterday. However, on April 15, Kepler Capital maintained a Hold rating on Qiagen (NYSE: QGEN).

The company has a one-year high of $47.74 and a one-year low of $34.77. Currently, Qiagen has an average volume of 1.06M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Qiagen (QGEN) Company Description:

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.